Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Illinois
Clinical trial register · United States · industry-sponsored

Clinical Trials in Illinois, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9124 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 09 Oct 2026, 03:16 UTC
9124
Studies in scope
industry-sponsored, all four open statuses
4956
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 64 Florida 51 Illinois 32 Georgia 26 Connecticut 25
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca109 AbbVie103 Eli Lilly and Company70 Novartis Pharmaceuticals62 Merck Sharp & Dohme LLC62 Clear sponsor filter
State
California64 Florida51 Illinois32 Georgia26 Connecticut25
All 45 states
Target enrolment
to

Trials with a site in Illinois

32 of 9124 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Amgen
Phase 3
126
California, Illinois, Virginia
2026-08-21
Recruiting
Amgen
Phase 3
950
Arizona, California, Florida, Illinois, Iowa, Kansas, Louisiana, Maryland
2026-07-29
Recruiting
Amgen
Phase 3
3,200
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-23
Recruiting
Amgen
Phase 3
304
California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts
2026-05-27
Recruiting
Amgen
Phase 3
300
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2026-05-11
Recruiting
Amgen
Phase 2
30
Arkansas, Florida, Illinois, West Virginia
2026-05-07
Recruiting
Amgen
Phase 1
160
Arizona, Florida, Illinois, Minnesota, New York, Tennessee, Virginia
2026-04-21
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
California, Illinois, Indiana, Maine, Tennessee, Texas
2026-04-08
Recruiting
Amgen
Phase 3
270
Alabama, Alaska, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Recruiting
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Active, closed
Amgen
Phase 3
350
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-08-18
Recruiting
Amgen
Phase 3
12,800
Alabama, Arizona, California, Delaware, Florida, Georgia, Idaho, Illinois
2025-07-25
Active, closed
Amgen
Phase 3
1,105
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-17
Active, closed
Amgen
Phase 2
252
California, Connecticut, Florida, Illinois, Minnesota, New York, North Carolina, Pennsylvania
2025-02-26
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Alabama, Arizona, California, Colorado, Connecticut, Florida, Hawaii, Illinois
2025-01-13
Active, closed
Amgen
Phase 3
707
Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Michigan
2024-12-09
Active, closed
Amgen
Phase 2
409
Alabama, California, Florida, Georgia, Illinois, Louisiana, Michigan, Montana
2024-11-07
Recruiting
Amgen
Phase 1
220
California, Illinois, Michigan, South Dakota, Texas, Washington
2024-10-07
Active, closed
Amgen
Phase 3
315
California, Florida, Illinois, Iowa, Michigan, New York, Ohio, Texas
2024-09-09
Recruiting
Amgen
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Michigan
2024-07-17
Active, closed
Amgen
Phase 3
89
Arizona, Illinois, Michigan, Nevada, New Jersey, Oregon, Pennsylvania, Tennessee
2024-07-05
Active, closed
Amgen
Phase 3
563
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2024-06-05
Active, closed
Amgen
Phase 1/2
94
Arkansas, California, Florida, Illinois, Massachusetts, Nevada, Pennsylvania, Texas
2024-05-30
Active, closed
Amgen
Phase 1
120
California, Colorado, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Missouri
2024-05-29
Recruiting
Amgen
Phase 3
750
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, New Mexico, New York
2023-11-16
Active, closed
Amgen
Phase 3
509
Alabama, Alaska, Arkansas, California, Illinois, Indiana, Iowa, Kentucky
2023-05-31
Active, closed
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05284747Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
DrugsRepatha·Evolocumab
Amgen
Phase 4
6,019
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2022-10-26
Active, closed
Amgen
Phase 1/2
181
California, Illinois, Maryland, Michigan, New York, Pennsylvania, Tennessee, Texas
2021-01-04
Active, closed
Amgen
Phase 3
145
Arkansas, California, Colorado, Florida, Idaho, Illinois, Louisiana, Maryland
2020-02-26
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Sotorasib·Afatinib
Amgen
Phase 1
610
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2019-12-17
Active, closed
Amgen
Phase 3
457
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2019-07-19
Active, closed
Amgen
Phase 1
269
California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland, Michigan
2017-12-26
Rows per page Showing 1–32 of 32
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-usa/state/illinois

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,124 studies in total at the last sync on 09 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 32 of those studies with a site in Illinois that also match the filters currently applied.

How many clinical trials are recruiting in Illinois?

14 of the 32 studies on this page are recruiting new participants as of the 09 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Illinois), 32 studies
PhaseStudiesRecruitingShare
Phase 3201062.5%
Phase 16318.8%
Phase 2319.4%
Phase 1/2206.3%
Phase 4103.1%

Most active sponsors

Lead sponsors with the most studies (Illinois)
Lead sponsorStudiesRecruiting
Amgen3214
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.